Lymphoma Trials

Genentech GO40554

A phase I/II study of BTCT4465A in patients who do not achieve CR to 1L therapy for DLBCL and as 1L therapy for patients unfit to receive full-dose anthracycline-based chemotherapy Regulatory Packet sent to Sponsor.

TG Therapeutics TG-1501-101

A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma

Aptose APTO-CG-806- 01

A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin’s Lymphomas

AstraZeneca/ Acerta D8227C00001 (ACE-LY-312)

AstraZeneca/ Acerta D8227C00001 (ACE-LY-312) A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Study Comparing the Efficacy and Safety of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Alone Versus in Combination with Acalabrutinib in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma.

UChicago IRB19-0072

Phase II study of pembrolizumab in combination with R-CHOP for patients with untreated, high-risk, non-germinal center-derived DLBCL

UChicago IRB19-0076

Phase II study of pembrolizumab for PD-L1 gene-altered, relapsed/refractory DLBCL

Fort Wayne North Office
(260) 484-8830
2514 E Dupont Road, Suite 100
Fort Wayne, IN 46825

Fort Wayne South Office
(260) 436-0800
7910 West Jefferson Boulevard, Suite 108
Fort Wayne, Indiana 46804

©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.

Winter Weather Alert:  Our clinics in Angola, Decatur, Bluffton, Hicksville, Wabash are closed Jan. 23rd.  Fort Wayne offices will be open unless Allen County has a RED advisory.  If Allen County is RED, Fort Wayne offices will be closed also.